I agree it would, but it’s unclear to me whether they are measuring drug effect on epilepsy.
If they are, it seems to me that Angelman might be a better indication to capture that.
According to the PMS global survey, epilepsy has a prevalence of ~19% in the in the 3-12 age group being assessed in the PMS study.
In comparison, there seems to be a much higher prevalence (60-70%) of epilepsy in Angelman syndrome in the same age group (Angelman Syndrome Foundation).
I note that all four Phase 2 studies exclude participants with an unstable seizure profile.
Phase 2, page-23
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |